It will be rewarding to perform a prospective drug study with ACAA1 as a valid druggable target for improving the pathological characteristics and cognitive impairment symptoms in AD patients with deficiency of ACAA1 enzyme activity and impaired VLCFA β-oxidation. The gene discussed is ACAA1; the disease is Cognitive impairment.